The British Journal of Psychiatry (2007) 190: 91-93. doi: 10.1192/bjp.bp.106.024794
© 2007 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by BARBUI, C.
Right arrow Articles by GARATTINI, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BARBUI, C.
Right arrow Articles by GARATTINI, S.

EDITORIALS

Regulatory policies on medicines for psychiatric disorders: is Europe on target?

CORRADO BARBUI

Department of Medicine and Public Health, University of Verona, Verona

SILVIO GARATTINI

Institute of Pharmacological Research Mario Negri, Milan, Italy

Correspondence: Dr Corrado Barbui, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, Ospedale Policlinico, 37134 Verona, Italy. Tel: +39 045 8076418; fax: +39 045 585871; email: corrado.barbui{at}univr.it

Declaration of interest S.G. was a member of the Committee for Proprietary Medicinal Products.

The European Medicines Agency (EMEA) is the regulatory body that provides the institutions of the European Community with the best possible scientific advice on the quality, safety and efficacy of medicinal products. Drugs approved by the EMEA are automatically marketable in all the European member states. Since the beginning of the EMEA’s activities a number of drugs acting on the central nervous system obtained marketing authorisation. This editorial highlights some aspects of the EMEA rules that may negatively affect the evaluation of medicines for psychiatric disorders.


Related articles in BJP:

Peter Tyrer
BJP 2007 190: 188. [Full Text]  



This article has been cited by other articles:


Home page
 Evid. Based Ment. HealthHome page
C. Barbui, A. Cipriani, T. A Furukawa, G. Salanti, J. P T Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I. M Omori, and J. R Geddes
Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
Evid. Based Ment. Health, November 1, 2009; 12(4): 101 - 104.
[Full Text] [PDF]